Recurrent multiple CNS hemangioblastomas with VHL disease treated with pazopanib: a case report and literature review
|Published in||CNS Oncology. 2015, vol. 4, no. 6, p. 387-92|
|Abstract||Hemangioblastoma is a rare benign neoplasm, accounting for less than 2% of all primitive brain tumors. It may arise sporadically in a solitary form, or associated with Von Hippel-Lindau (VHL) disease with multiple tumors. Surgery is the mainstay treatment, but management is challenging in case of recurrent and/or multiple tumors. VHL protein is defective in both forms of hemangioblastoma, leading to the accumulation of hypoxia-inducible factor, stimulating angiogenesis via VEGF and PDGF mainly. Here, we report a 37-year-old woman's case with recurrent and rapidly progressive VHL-associated hemangioblastomas, causing severe disability. She was treated 24 months with pazopanib, a multityrosine kinase inhibitor (TKI) targeting VEGF and PDGF-β pathways. Despite moderate radiological changes, progressive improvement in her clinical condition persisting over 3 years was observed. Inhibiting angiogenesis is a therapeutic option that may improve the quality of life and the autonomy of VHL patients disabled with multiple hemangioblastomas.|
This document has no fulltext available yet, but you can contact its author by using the form below.
Faculté de médecine / Section de médecine clinique / Département de médecine interne des spécialités
|Research groups||La Sclérose en plaques (908)|
Immunothérapie des cancers (42)
|MIGLIORINI, Denis et al. Recurrent multiple CNS hemangioblastomas with VHL disease treated with pazopanib: a case report and literature review. In: CNS Oncology, 2015, vol. 4, n° 6, p. 387-92. https://archive-ouverte.unige.ch/unige:84085|